The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia

Urology

Volumn 53, Issue 1, 1999, Pages 121-125

  Giovannucci, Edward ^a,b   Platz, Elizabeth A ^b   Stampfer, Meir J ^a,b   Chan, Andrew ^c   Krithivas, Krishna ^c   Kawachi, Ichiro ^a   Willett, Walter C ^a,b   Kantoff, Philip W ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN RECEPTOR; ANDROSTANOLONE; DNA; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE REPEAT; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; RECEPTOR GENE;

ADULT; AGED; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; RECEPTORS, ANDROGEN; TRINUCLEOTIDE REPEATS;

EID: 0032956520     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00468-3     Document Type: Article

References (20)

1. Caine M., Raz S., Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol. 47:1975;193-202.
2. Isaacs J.T. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate. 3:(suppl):1990;1-7.
3. Price H., McNeal J.E., Stamey T.A. Evolving patterns of tissue composition in benign prostatic hyperplasia as a function of specimen size. Hum Pathol. 21:1990;578-585.
4. La Spada A.R., Wilson E.M., Lubahn D.B., et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 352:1991;77-79.
5. Igarashi S., Tanno Y., Onodera O., et al. Strong correlation between the number of CAG repeats in androgen receptor genes and the clinical onset of features of spinal and bulbar muscular atrophy. Neurology. 42:1992;2300-2302.
6. Tut T.G., Ghadessy F.J., Trifiro M.A., et al. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab. 82:1997;3777-3782.
7. Chamberlain N.L., Driver E.D., Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen N-terminal domain affect transactivation function. Nucleic Acids Res. 22:1994;3181-3186.
8. n-expanded neuronopathies . Hum Mol Genet. 4:1995;523-527.
9. Choong C.S., Kemppainen J.A., Zhou Z.X., et al. Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol Endocrinol. 10:1996;1527-1535.
10. Coetzee G.A., Ross R.K. Re prostate cancer and the androgen receptor (letter) . J Natl Cancer Inst. 86:1994;872-873.
11. Giovannucci E., Stampfer M.J., Krithivas K., et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA. 94:1997;3320-3323.
12. Stanford J.L., Just J.J., Gibbs M., et al. Polymorphic repeats in the androgen receptor gene molecular markers of prostate cancer risk . Cancer Res. 57:1997;1194-1198.
13. Ingles S.A., Ross R.K., Yu M.C., et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 89:1997;166-170.
14. Barry M.J., Fowler F.J. Jr. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 148:1992;1549-1557.
15. Giovannucci E., Rimm E.B., Chute C.G., et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 140:1994;989-1002.
16. Welch G., Kawachi I., Barry M.J., et al. Distinction between symptoms of voiding and filling in benign prostatic hyperplasia findings from the Health Professionals Follow-up Study . Urology. 51:1998;422-427.
17. Walsh P.C. Treatment of benign prostatic hyperplasia (editorial). N Engl J Med. 335:1996;586-587.
18. Gormley G.J., Stoner E., Bruskewitz R.C., et al. The effect of finasteride in men with benign prostatic hyperplasia the Finasteride Study Group . N Engl J Med. 327:1992;1185-1191.
19. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 22:1993;291-299.
20. Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 335:1996;533-539.